State Action
CCAGW Urges Vermont Senators to Oppose H. 121
H. 121 will fail to achieve its objective of protecting consumer privacy
CCAGW Urges Kansas Senate Ways and Means Committee to Accept the 340B Amendment
The Kansas House Appropriations Committee’s amendment to Substitute for SB514 eliminates proposed changes to the federal 340B drug pricing program.
CCAGW Urges Missouri Senators to Oppose Senate Bills 751, 843, 844, and 1105
S.B. 751, S.B. 843, S.B. 844, and S.B. 1105 which would each create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Missouri.
CCAGW Urges Missouri Representatives to Oppose House Bills 1627, 1628 and 2267
H.B. 1627, H.B. 1628, and H.B. 2267 would each create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Missouri.
CCAGW Urges Mississippi Legislators to Oppose House Bill 1265
HB 1265 would create unnecessary regulatory barriers to undermine the effectiveness of PBMs in Mississippi.
CCAGW Urges California Legislators to Oppose Senate Bill 966
SB 966 would create unnecessary regulatory barriers to undermine the effectiveness of pharmaceutical benefit managers (PBMs) in the Golden State.
CCAGW Urges Pennsylvania Legislators to Oppose Senate Bill 1000
SB 1000 creates unnecessary regulatory barriers that will undermine the effectiveness of PBMs in Pennsylvania.
CCAGW Urges Kansas Legislators to Oppose Amendment to SB 514
The move to amend Substitute for SB 514 will change how the federal 340B drug pricing program operates in the Sunflower State.
CCAGW Urges Governor Reeves to Veto House Bill 728
HB 728 would change how the federal 340B program operates in Mississippi.
CCAGW Urges Kentucky Representatives to Oppose SB 188
SB 188 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Kentucky.
CCAGW Urges Governor Youngkin to Veto Senate Bill 274
SB 274 would impose price controls on prescription drugs. Price controls distort markets, hurt innovation, and exacerbate the problems they are created to fix.
CCAGW Urges Illinois Legislators to Oppose House Bill 4548
HB 4548 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Illinois.
